mRNA 1608
Alternative Names: Herpes simplex virus vaccine - Moderna Therapeutics; mRNA-1608Latest Information Update: 31 Dec 2025
At a glance
- Originator Moderna Therapeutics
- Class RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Herpes simplex virus infections
Most Recent Events
- 20 Nov 2025 Discontinued - Phase-I/II for Herpes simplex virus infections in USA (IM) due to strategic prioritization
- 25 Apr 2025 Moderna Therapeutics completes a phase I/II trial for Herpes simplex virus infections in USA (IM, Injection) (NCT06033261)
- 27 Mar 2024 Moderna Therapeutics completes enrolment in its phase-I/II trial for Herpes simplex virus infections in USA (IM, Injection) prior to March 2024 (NCT06033261)